In this study, we tested the blocking activity of convalescent plasma from COVID-19-recovered subjects by cell–cell fusion assays using SARS-CoV-2-S- or SARS-CoV-S-transfected 293 T as the effector cells and ACE2-expressing 293 T as the target cells. Here, ACE2 is linked to COVID-19.